1.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR003583, ET743SAR3002, NCT00210665
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 21
Sponsor: Other
Protocol IDs: CCLG-EPSSG-NRSTS-2005, EU-20620, EUDRACT-2005-001139-31, UKCCSG-CTA-21275/0215/001/0001, CCLG-EpSSG-STS-2006-03, NCT00334854
|
|
3.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 50
Sponsor: NCI, Other
Protocol IDs: CDR0000487560, COG-ARST0531, ARST0531, NCT00354835
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: CRUK-VORTEX, EU-20678, ISRCTN76456502, CRCTU-SA3002, NCT00423618
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08SARC01, NCT00870701
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 6 months to 21 years
Sponsor: Other
Protocol IDs: CWS-2007-HR, 4033024 (BfArM), 293/2007AMG1 (Ethikkommission), 2007-001478-10, A2007/14 (Kinderkrebsstiftung), 498 (Krebsstudienregister), NCT00876031
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 10-154, NCT01223248
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7389-G000-309, NCT01327885
|
|
9.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-62092-22092, EORTC-62092, EORTC-22092, EU-21113, STRASS, NCT01344018
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 15 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR018004, ET743SAR3007, NCT01343277
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 15 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TH-CR-406/SARC021, NCT01440088
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 20 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7040-J081-301, NCT01677624
|
|
13.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 15 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR017269, ET743SAR3006, NCT01692678
|
|
14.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ISG-STS 10-01, NCT01710176
|
|
15.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 72
Sponsor: Other
Protocol IDs: GEIS01-07, NCT00541840
|
|
16.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: ASSG01, NCT00753727
|
|
17.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000628781, UCDCC-216, BAYER-UCDCC-216, NCT00805727
|
|
18.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AVF4761s, 200911736, NCT01106872
|
|
19.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01412, 10-049, CDR0000680558, MSKCC-10049, U01CA069856, 8406, NCT01154452
|
|
20.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 3 to 75
Sponsor: Other
Protocol IDs: NDV-HUJ-HMO-CTIL, NCT01174537
|
|
21.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BBI608-201, NCT01325441
|
|
22.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11-104, NCT01418001
|
|
23.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: RETROWTS, NCT01566123
|
|
24.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 12 and over
Sponsor: Other
Protocol IDs: 2010-0700, NCT01590069
|
|
25.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 12-100, NCT01659203
|
Mobile | Español